(Total Views: 566)
Posted On: 08/13/2021 3:50:33 AM
Post# of 72440
JFM brought this important point of view to my attention
“IMO shows confidence in what he has done with B with K and now everyone waits for results...
But PRs indicates that he is clearly not "all eggs in one basket"...
OM (Phase III) and
UP (Phase IIb) appear to be well to Clinical Trials
UC formulation...PR'd
...IMO he allocates limited dollars prudently...for multiple opportunities”
1. Kevetrin: Oncology Reports, a leading oncology journal, supporting the therapeutic potential of Kevetrin, the Company’s p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML). AML accounts for approximately one-quarter to one-third of all leukemias worldwide and has a 5-year survival rate of only 24 percent.
2. OM: The Company had previously engaged Locust Walk to assess the value of its clinical assets, which included recently an in-depth assessment of the commercial opportunity of oral rinse Brilacidin-OM—a Phase 3-ready, FDA Fast Track-designated clinical asset in late-stage development targeting a substantial untapped market in supportive cancer care. This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.
3. Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis … visits have been completed in its Phase 2b clinical study of oral Prurisol in moderate-to-severe chronic
4. Cellceutix Selects Dr. Reddy’s Laboratories for Formulation of Brilacidin for Opthalmic and Otitis Infections
Cellceutix Selects Dr. Reddy’s Laboratories for Formulation of Brilacidin for Opthalmic and Otitis Infections … , custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs … , announces today that the Company has concluded negotiations with formulation developers and selected … as OctoPlus specializes in complex formulations. We are extremely optimistic about Brilacidin for … Exchange-listed company traded under the ticker “RDY”, for the formulation of the Company’s defensin … expertise in both APIs and formulation development will assist Cellceutix in the clinical
Now IMO as for Leo? He B BIZZY BOY. I like him. Lol
“IMO shows confidence in what he has done with B with K and now everyone waits for results...
But PRs indicates that he is clearly not "all eggs in one basket"...
OM (Phase III) and
UP (Phase IIb) appear to be well to Clinical Trials
UC formulation...PR'd
...IMO he allocates limited dollars prudently...for multiple opportunities”
1. Kevetrin: Oncology Reports, a leading oncology journal, supporting the therapeutic potential of Kevetrin, the Company’s p53-modulating anti-cancer drug candidate, in treating Acute Myeloid Leukemia (AML). AML accounts for approximately one-quarter to one-third of all leukemias worldwide and has a 5-year survival rate of only 24 percent.
2. OM: The Company had previously engaged Locust Walk to assess the value of its clinical assets, which included recently an in-depth assessment of the commercial opportunity of oral rinse Brilacidin-OM—a Phase 3-ready, FDA Fast Track-designated clinical asset in late-stage development targeting a substantial untapped market in supportive cancer care. This renewed engagement is a continuation of Innovation Pharmaceutical’s business relationship with Locust Walk toward realizing the market potential of the Company’s pipeline.
3. Innovation Pharmaceuticals Completes Final Patient Visit in Phase 2b Study of Oral Prurisol for Psoriasis … visits have been completed in its Phase 2b clinical study of oral Prurisol in moderate-to-severe chronic
4. Cellceutix Selects Dr. Reddy’s Laboratories for Formulation of Brilacidin for Opthalmic and Otitis Infections
Cellceutix Selects Dr. Reddy’s Laboratories for Formulation of Brilacidin for Opthalmic and Otitis Infections … , custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs … , announces today that the Company has concluded negotiations with formulation developers and selected … as OctoPlus specializes in complex formulations. We are extremely optimistic about Brilacidin for … Exchange-listed company traded under the ticker “RDY”, for the formulation of the Company’s defensin … expertise in both APIs and formulation development will assist Cellceutix in the clinical
Now IMO as for Leo? He B BIZZY BOY. I like him. Lol
(6)
(0)
Ronald A Phillips
Scroll down for more posts ▼
